Glenn Burlingame

Glenn advises emerging and established clients in connection with corporate finance transactions, mergers and acquisitions and securities law matters including initial public offerings, secondary offerings, shelf takedowns, private investments in public equity (PIPEs), registered direct transactions, venture financings and other securities offerings. He has extensive experience representing both buyers and sellers in connection with stock purchases, asset purchases and merger transactions, including acquisitions anddivestitures of distressed companies.

Glenn advises public and private companies in connection with commercial contracts, executive employment agreements, separation agreements and compensation plans. He also provides ongoing counsel to public companies regarding SEC reporting, securities law compliance, and corporate governance. He represents companies in awide range of industries, including pharmaceutical, medical device, manufacturing, e-commerce, media, entertainment, food and beverage, software and financial services (including fintech and cryptocurrency). His international experience includes representing companies in Europe, Asia, Australia and Israel.

Glenn’s representative transactions include:

• Zynex, Inc. (NASDAQ: ZYXI), a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring (NASDAQ: ZYXI), in a $60 million 144A private offering of convertible notes
• Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents, in a merger with IsoRay, Inc., now known as Perspective Therapeutics, Inc. (NYSE American: ISR)
• Verb Technology Company, Inc. (NASDAQ: VERB), a leader in interactive video-based sales-enablement applications, in the sale of its assets that comprised its direct sales and life sciences software-as-service applications, to Scaleworks, Inc.
• MKD Technologies Inc., a company headquartered in Taiwan that focuses on automotive electronics design and manufacturing, in connection with a $230 million business combination agreement with Cetus Capital Acquisition Corp. (NASDAQ: CETUU), a blank check company
• Zynex, Inc. (NASDAQ: ZYXI) in its $31 million acquisition of Kestrel Labs, Inc., a laser-based, noninvasive patient monitoring technology company
• The Glimpse Group (NASDAQ: VRAR), an immersive technology platform company, in its $27 million acquisition of Sector 5 Digital LLC, an immersion content developer.
• DSS, Inc. (NYSE American: DSS), a multinational corporation with a diverse portfolio of businesses, including product packaging, biotechnology, direct marketing, commercial lending, securities and investment management, and alternative trading, in a wide variety of transactions, including loans, acquisitions, divestitures and entity formations.

Mr. Burlingame received his Juris Doctorate from New York University School of Law

Mr. Burlingame is admitted to practice in New York.